26 Mar 2022
New Long-Term Complete Skin Clearance Data for BIMZELX[®]▼ (bimekizumab) in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting
Read More
25 Mar 2022
25 Mar 2022
New UCB data analysis adds to demonstrated efficacy of romosozumab▼ to reduce the risk of fractures
Read More
25 Mar 2022
WCO-IOF-ESCEO 2022 – Post-hoc analysis on the proportion of patients treated with EVENITY[® ]▼(romosozumab) reaching surrogate threshold effect that predicts fracture risk reduction
Read More
18 Mar 2022
18 Mar 2022
